Evidence map›Paper›PMID 39680249›Full record

ReviewCurrent hypertension reports2024

Diagnosis of Primary Aldosteronism without Discontinuation of Interfering Antihypertensive Medications.

Zhichao Dong, Xiaoxiao Song, Minyue Jia, Jinliang Chen, Yuhao Zhang, Hanxiao Yu, Yongli Ji, Lizhen Shan, Tianyue Zhang, Chao Zheng and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhichao Dong *Department of Urology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0009-0009-3356-8763
Xiaoxiao Song *Department of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China.ORCID http://orcid.org/0000-0001-5911-3307
Minyue JiaDepartment of Ultrasonography, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jinliang ChenDepartment of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China.
Yuhao ZhangDepartment of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China.
Hanxiao YuCenter for Basic and Translational Research, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yongli JiDepartment of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China.
Lizhen ShanDepartment of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China.
Tianyue ZhangDepartment of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China.
Chao ZhengDepartment of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China. chao_zheng@zju.edu.cn.ORCID http://orcid.org/0000-0003-2157-2609
Jiaming WenDepartment of Urology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. wenjiaming@zju.edu.cn.
Xiaohong XuDepartment of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China. xuxiaoh@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewOne of the challenges in the diagnosis and management of primary aldosteronism (PA), the most common type of secondary hypertension with curative potential, is the modification of antihypertensive medications. We seek to explore whether these medications can be continued during the diagnostic process of PA to minimize the duration and risks associated with medication adjustments. RECENT

findingsWe searched PubMed for eligible original literature between 1990 and 2024 using the following keywords: (screening) AND (primary aldosteronism); (confirmatory) AND (primary aldosteronism); (adrenal vein sampling) AND primary aldosteronism). Some recent studies support the feasibility of PA-related tests and even adrenal vein sampling (AVS) without the need to discontinue antihypertensive medications in certain cases. In this review, we propose a management approach that considers the specific effects of antihypertensive medications on the RAAS axis and the patient's disease phenotype. Based on this, we suggest a strategy that enables the diagnosis of PA in certain patients without discontinuing their antihypertensive medications.

Indexed as

Antihypertensive AgentsHyperaldosteronismHypertensionAdrenal GlandsHumansRenin-Angiotensin SystemAntihypertensive AgentsAdrenal vein samplingAldosteroneAldosterone to renin ratioPrimary aldosteronismRenin

Identifiers

PMID39680249

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.